- Will the industry consolidate, decentralize, or undergo a bimodal transformation? - How will the current trends affect the major market segments? - Which companies will enter the market and which will not survive? This new report from Venture Planning Group provides technological know-how of leading life science intermediates companies. The report presents: Internally developed and acquired technologies, and related capabilities. Proprietary technologies and patent litigations. The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia. Contains 35 pages Research Beam Model: Research Beam Product ID: 302198 0 USD New
2015 Life Science Intermediates Market Consolidation: Who will not survive?
 

2015 Life Science Intermediates Market Consolidation: Who will not survive?

2015 Life Science Intermediates Market Consolidation: Who will not survive?

Category : Materials & Chemicals
Published On : May  2015
Pages : 35



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
- Will the industry consolidate, decentralize, or undergo a bimodal transformation? 
- How will the current trends affect the major market segments?
- Which companies will enter the market and which will not survive?
This new report from Venture Planning Group provides technological know-how of leading life science intermediates companies. The report presents:
  • Internally developed and acquired technologies, and related capabilities.
  • Proprietary technologies and patent litigations.
The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia.

Contains 35 pages



Enquiry Before Buy